Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Vaccine
; 38(46): 7205-7212, 2020 10 27.
Article
in English
| MEDLINE | ID: covidwho-779733
ABSTRACT
The development of an effective vaccine against SARS-CoV-2 is urgently needed. We generated SARS-CoV-2 RBD-Fc fusion protein and evaluated its potency to elicit neutralizing antibody response in mice. RBD-Fc elicited a higher neutralizing antibodies titer than RBD as evaluated by a pseudovirus neutralization assay and a live virus based microneutralization assay. Furthermore, RBD-Fc immunized sera better inhibited cell-cell fusion, as evaluated by a quantitative cell-cell fusion assay. The cell-cell fusion assay results correlated well with the virus neutralization potency and could be used for high-throughput screening of large panels of anti-SARS-CoV-2 antibodies and vaccines without the requirement of live virus infection in BSL3 containment. Moreover, the anti-RBD sera did not enhance the pseudotyped SARS-CoV-2 infection of K562 cells. These results demonstrate that Fc fusion can significantly improve the humoral immune response to recombinant RBD immunogen, and suggest that RBD-Fc could serve as a useful component of effective vaccines against SARS-CoV-2.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Immunoglobulin Fc Fragments
/
Viral Vaccines
/
Coronavirus Infections
/
Antibodies, Neutralizing
/
Pandemics
/
Spike Glycoprotein, Coronavirus
/
Antibodies, Viral
Type of study:
Experimental Studies
Topics:
Vaccines
Limits:
Animals
/
Female
/
Humans
Language:
English
Journal:
Vaccine
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS